报价延迟最少15分钟:2026/01/09 23:05 EST
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
16.8 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-3.94/-1.59
|
|
企业价值
803.97M
|
| 资产负债 |
|
每股账面净值
0.34
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older. |
